ECSP982539A - FARNESIL TRANSFERASE INHIBITORS COMBINED WITH HMG CoA REDUCTASE INHIBITORS FOR CANCER TREATMENT - Google Patents
FARNESIL TRANSFERASE INHIBITORS COMBINED WITH HMG CoA REDUCTASE INHIBITORS FOR CANCER TREATMENTInfo
- Publication number
- ECSP982539A ECSP982539A ECSP982539A ECSP982539A EC SP982539 A ECSP982539 A EC SP982539A EC SP982539 A ECSP982539 A EC SP982539A EC SP982539 A ECSP982539 A EC SP982539A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitors
- hmg coa
- coa reductase
- cancer treatment
- combined
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 229950008696 farnesil Drugs 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 239000003558 transferase inhibitor Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un procedimiento para tratar cáncer en un mamífero, incluida un ser humano, administrando al citado mamífero un inhibidor de la FTSA combinado con un inhibidor de la HMG CoA.The present invention relates to a method of treating cancer in a mammal, including a human, by administering said mammal an FTSA inhibitor combined with an HMG CoA inhibitor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982539 ECSP982539A (en) | 1998-06-16 | 1998-06-16 | FARNESIL TRANSFERASE INHIBITORS COMBINED WITH HMG CoA REDUCTASE INHIBITORS FOR CANCER TREATMENT |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982539 ECSP982539A (en) | 1998-06-16 | 1998-06-16 | FARNESIL TRANSFERASE INHIBITORS COMBINED WITH HMG CoA REDUCTASE INHIBITORS FOR CANCER TREATMENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP982539A true ECSP982539A (en) | 1999-02-11 |
Family
ID=42043459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP982539 ECSP982539A (en) | 1998-06-16 | 1998-06-16 | FARNESIL TRANSFERASE INHIBITORS COMBINED WITH HMG CoA REDUCTASE INHIBITORS FOR CANCER TREATMENT |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP982539A (en) |
-
1998
- 1998-06-16 EC ECSP982539 patent/ECSP982539A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT971713E (en) | USE OF COLINESTERASE INHIBITORS FOR TREATMENT OF ATENTION DISORDERS | |
| DK1169060T3 (en) | Sodium channel blocker preparations and their use | |
| MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
| BR0316238A (en) | Combination chemotherapy comprising a mek and capecitabine inhibitor for cancer treatment | |
| HN2001000244A (en) | SPIROPIRIMIDIN INHIBITORS - 2, 4, 6 - TRIONA METALOPROTEINASAS. | |
| BRPI0408476A (en) | methods to improve skin quality | |
| BR0013081A (en) | Metalloproteinase-inhibiting pyrimidine-2,4,6-triones | |
| IL147017A0 (en) | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES | |
| BR9710686A (en) | Method of treatment of malignant tumors with analogous thyroxines without significant hormonal activity. | |
| EA200500859A1 (en) | QUINOLINILPYRROPYRAZOLES | |
| EP1098642A4 (en) | METHOD FOR TREATING CONDITIONS MODULATED BY LACTOSYLCERAMIDES | |
| MY138883A (en) | Use of asiatic acid for treatment of cencer | |
| ATE510553T1 (en) | BETA-2-GLYCOPROTEIN 1 AS ANGIOGENESIS INHIBITOR | |
| DE60019121D1 (en) | KALIUMKANÄLEÖFFNER | |
| IL162384A0 (en) | Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases | |
| ATE430572T1 (en) | USE OF SPONGOSIN (2-METHOXYADENOSINE) FOR THE TREATMENT OF PAIN, ESPECIALLY HYPERALGESIA | |
| PA8453601A1 (en) | FARNESIL TRANSFERASE INHIBITORS COMBINED WITH HMG COA REDUCTASE INHIBITORS FOR CANCER TREATMENT | |
| UY27772A1 (en) | TRIARILOXIARILOXIPIRIMIDIN-2,4,6- METALOPROTEINASE TRIONA INHIBITORS. | |
| BR0315942A (en) | Treatment of diseases and conditions mediated by increased phosphorylation | |
| ATE327973T1 (en) | POLYAMINE ANALOGUES AS CYTOTOXIC AGENTS | |
| ATE516027T1 (en) | ORAZAMID OROTAT TO PREVENT LIVER DAMAGE | |
| EA200100930A1 (en) | METHOD OF TREATMENT COPD | |
| SE0100684D0 (en) | New subject matter | |
| PL357179A1 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers | |
| ECSP982539A (en) | FARNESIL TRANSFERASE INHIBITORS COMBINED WITH HMG CoA REDUCTASE INHIBITORS FOR CANCER TREATMENT |